Abbott (NYSE:ABT) and Dexcom (Nasdaq:DXCM) both submitted legal briefs angling for another trial in an ongoing continuous glucose monitor (CGM) patent spat. In March, the U.S. District Court for the District of Delaware found that Dexcom violated a single patent belonging to Abbott and its FreeStyle Libre sensors. However, the court found that Dexcom did […]
Dexcom
Tandem pairs Mobi automated insulin pump with Dexcom G7
Tandem Diabetes Care (Nasdaq:TNDM) announced today that it integrated its Mobi insulin pump with the Dexcom G7 continuous glucose monitor (CGM). Already compatible with the previous-generation G6, Mobi now pairs with Dexcom’s latest-generation CGM. San Diego-based Tandem launched Mobi, the world’s smallest, durable automated insulin delivery (AID) system in the U.S. this year. It received […]
Dexcom launches new sensor in the UK
Dexcom announced today that it launched the Dexcom ONE+ continuous glucose monitor (CGM) in the UK. ONE+ uses Dexcom’s established sensor design, with the company incorporating feedback from users and healthcare professionals to build it. The company said this ensured an easy-to-use, highly effective CGM experience for people treating type 1 or type 2 diabetes […]
Dexcom stock slides despite Q1 beats, sales guidance increase
Dexcom shares took a hit after hours today on first-quarter results that came in ahead of the consensus forecast on Wall Street. Shares of DXCM dipped about 7% to $128.40 apiece after the market closed today. MassDevice’s MedTech 100 Index — which includes stocks of the world’s largest medical device companies — closed the day […]
Study highlights benefits of automated insulin delivery for children in UK
A study in the UK demonstrated significant improvements in HbA1c for users of automated insulin delivery technologies. This comes on the heels of a UK NHS initiative to provide tens of thousands of children and adults with type 1 diabetes in the country with an artificial pancreas. The study aimed to assess the efficacy of […]
Non-insulin, basal CGM use exceeds analysts’ expectations, Dexcom and Abbott to benefit
William Blair analyst Margaret Kaczor reported surprise at the increase in users of CGM within the non-insulin and basal insulin populations. Kaczor expects Dexcom and Abbott to benefit from the trend with their next-generation CGM offerings after meetings with both companies’ management. Both companies launched next-gen CGMs in recent years (Dexcom G7 and Abbott FreeStyle […]
10 new, innovative medical devices to watch for in 2024
By Senior Editor Danielle Kirsh and Associate Editor Sean Whooley Significant medical device launches are coming in 2024. Think pulsed field ablation, diabetes treatment tech, surgical robotics and more. Pulsed field ablation news took over at the end of 2023 and the start of 2024, with Medtronic and Boston Scientific garnering significant regulatory approvals. Surgical […]
Dexcom, MD Revolution partner to integrate CGM into remote care platform
MD Revolution today announced a partnership with Dexcom to integrate CGM into its remote care management platform. Dexcom develops continuous glucose monitoring technology (CGM), including its latest-generation G7. The system pairs with smartphones — and now Apple Watches — to monitor the glucose levels of people with diabetes. MD Revolution’s remote care management platform integrates […]
Tandem Diabetes Care taps miniaturization and automation for its latest systems
Tandem Diabetes Care (Nasdaq:TNDM) EVP and Chief Strategy Officer Elizabeth Gasser didn’t exactly plan for the whirlwind past year or so. In the space of about two months, Tandem announced continuous glucose monitor (CGM) integration with the latest-generation technology from Dexcom and Abbott, launched its Tandem Source diabetes management platform and began the rollout of […]
The biggest diabetes tech news out of ATTD 2024
Every year, the diabetes community comes together for the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD). In the 17th installment at the start of this month, some of the biggest names shared new studies and technologies set to advance the diabetes space. Dexcom, Abbott, Medtronic and more contributed on their end, while […]
FDA clears first over-the-counter CGM from Dexcom
Dexcom announced today that the FDA cleared its Stelo glucose biosensor that does not require a prescription. This marks the first FDA clearance for a continuous glucose monitoring (CGM) technology for over-the-counter use. In January, Dexcom first announced that it submitted the new Stelo sensor to the FDA for review at the end of last […]
